New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:04 EDTUTHR, SUPNSupernus receives $2M milestone payment for launch of Orenitram
Supernus Pharmaceuticals (SUPN) announced that United Therapeutics Corporation (UTHR) has paid Supernus a $2M milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
News For SUPN;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
20:00 EDTSUPNSupernus management to meet with SunTrust
Subscribe for More Information
September 30, 2015
06:03 EDTUTHRUnited Therapeutics announces settlement of patent litigation with Sandoz
United Therapeutics announced that it has entered into a Settlement Agreement with Sandoz relating to ongoing litigation concerning certain patents relating to United Therapeutics' product, Remodulin Injection, and Sandoz's Abbreviated New Drug Application, or ANDA, seeking approval by the FDA to market a generic version of Remodulin. Under the Settlement Agreement, United Therapeutics granted to Sandoz a non-exclusive license to manufacture and commercialize the generic version of Remodulin described in its ANDA filing in the United States beginning on June 26, 2018, although Sandoz may be permitted to enter the market earlier under certain circumstances. The license included in the Settlement Agreement does not permit Sandoz the right to manufacture a generic version of any other United Therapeutics product, such as Tyvaso Inhalation Solution or Orenitram Extended-Release Tablets, nor does it grant any rights with respect to any technology associated with the Remodulin Implantable System being developed by the Company and Medtronic Inc., or the pre-filled semi-disposable pump system being developed by the Company and DEKA Research & Development Corp. The Settlement Agreement does not grant Sandoz any rights other than those required to launch Sandoz's generic version of Remodulin. In accordance with the Settlement Agreement, the parties will submit the Settlement Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
September 25, 2015
07:22 EDTUTHREuropean Society for Medical Oncology to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use